Osteoporosis International

, Volume 17, Issue 5, pp 664–671 | Cite as

Does an educational leaflet improve self-reported adherence to therapy in osteoporosis? The OPTIMA study

  • M. Guilera
  • M. Fuentes
  • M. Grifols
  • J. Ferrer
  • X. Badia
  • OPTIMA study investigators
Original Article

Abstract

Introduction

Adherence to treatment in osteoporosis remains poor. The aim of this study was to evaluate the effects of an educational leaflet on adherence to medication and to assess the association between adherence and health-related quality of life (HRQOL).

Methods

A naturalistic, observational, multi-center, prospective study of 12 months’ follow-up was performed. Consecutive post-menopausal women aged 50 years to 86 years starting treatment with raloxifene according to daily practice were enrolled from 126 primary care offices in Spain. The women were assigned to two study groups. Group A received an educational leaflet with general information about osteoporosis; group B followed current practice. To assess adherence to medication and HRQOL, the Morisky test and the EuroQoL questionnaire were administered. A total of 745 post-menopausal women (group A, n=366; group B n=379), with a mean age of 62 years, were included.

Results

Most patients in both study groups showed high adherence to raloxifene at the 3-month visit: 56.3% vs 62.7% for groups A and B, respectively; this proportion at the 12-month visit was 47.4% (P=0.15) and 52.5% (P=0.02), respectively. At baseline, “pain/discomfort” was the dimension showing the highest percentage of women reporting problems: 86.4% vs 83.2% in groups A and B, respectively (P=0.22). HRQOL improved in both groups throughout the study, with an overall mean increment in the EuroQoL visual analog scale (EQ VAS) of 9.2 at 12 months (P<0.01). Correlations between adherence and HRQOL were weak. After receiving an educational leaflet, young post-menopausal women suffering osteoporosis did not show improvement in adherence to therapy. HRQOL improved at 12-month follow-up under treatment.

Conclusion

No consistent correlation between adherence and HRQOL was found.

Keywords

Adherence HRQOL Osteoporosis Raloxifene 

References

  1. 1.
    Osteoporosis prevention, diagnosis, and therapy (2001) JAMA 285:785–795Google Scholar
  2. 2.
    Looker AC, Orwoll ES, Johnston CC Jr, et al (1997) Prevalence of low femoral bone density in older US adults from NHANES III. J Bone Miner Res 12:1761–1768PubMedCrossRefGoogle Scholar
  3. 3.
    Osteoporosis postmenopausica. Guía de práctica clinica (2003) Rev Clin Esp 203:496–506Google Scholar
  4. 4.
    Diaz CM, Carrasco de la Pena JL, Honorato PJ, et al (1997) Study of bone mineral density in lumbar spine and femoral neck in a Spanish population. Multicentre research project on osteoporosis. Osteoporos Int 7:59–64CrossRefPubMedGoogle Scholar
  5. 5.
    Cook DJ, Guyatt GH, Adachi JD, et al (1999) Development and validation of the mini-osteoporosis quality of life questionnaire (OQLQ) in osteoporotic women with back pain due to vertebral fractures. Osteoporosis Quality of Life Study Group. Osteoporos Int 10:207–213CrossRefPubMedGoogle Scholar
  6. 6.
    Kado DM, Browner WS, Palermo L, et al (1999) Vertebral fractures and mortality in older women: a prospective study. Study of Osteoporotic Fractures Research Group. Arch Intern Med 159:1215–1220CrossRefPubMedGoogle Scholar
  7. 7.
    Ray NF, Chan JK, Thamer M, et al (1997) Medical expenditures for the treatment of osteoporotic fractures in the United States in 1995: report from the National Osteoporosis Foundation. J Bone Miner Res 12:24–35PubMedCrossRefGoogle Scholar
  8. 8.
    Greendale GA, Barrett-Connor E, Ingles S, et al (1995) Late physical and functional effects of osteoporotic fracture in women: the Rancho Bernardo Study. J Am Geriatr Soc 43:955–961PubMedGoogle Scholar
  9. 9.
    Ettinger B, Black DM, Mitlak BH, et al (1999) Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 282:637–645CrossRefPubMedGoogle Scholar
  10. 10.
    Delmas PD, Ensrud KE, Adachi JD, et al (2002) Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trial. J Clin Endocrinol Metab 87:3609–3617PubMedCrossRefGoogle Scholar
  11. 11.
    Clowes JA, Peel NF, Eastell R (2004) The impact of monitoring on adherence and persistence with antiresorptive treatment for postmenopausal osteoporosis: a randomized controlled trial. J Clin Endocrinol Metab 89:1117–1123CrossRefPubMedGoogle Scholar
  12. 12.
    Turbi C, Herrero-Beaumont G, Acebes JC, et al (2004) Compliance and satisfaction with raloxifene versus alendronate for the treatment of postmenopausal osteoporosis in clinical practice: an open-label, prospective, nonrandomized, observational study. Clin Ther 26:245–256PubMedCrossRefGoogle Scholar
  13. 13.
    McDonald HP, Garg AX, Haynes RB (2002) Interventions to enhance patient adherence to medication prescriptions: scientific review. JAMA 288:2868–2879CrossRefPubMedGoogle Scholar
  14. 14.
    Haynes RB, McDonald HP, Garg AX (2002) Helping patients follow prescribed treatment: clinical applications. JAMA 288:2880–2883PubMedCrossRefGoogle Scholar
  15. 15.
    Blalock SJ, Currey SS, DeVellis RF, et al (2000) Effects of educational materials concerning osteoporosis on women’s knowledge, beliefs, and behavior. Am J Health Promot 14:161–169PubMedGoogle Scholar
  16. 16.
    Blalock SJ, DeVellis BM, Patterson CC, et al (2002) Effects of an osteoporosis prevention program incorporating tailored educational materials. Am J Health Promot 16:146–156PubMedGoogle Scholar
  17. 17.
    Morisky DE, Green LW, Levine DM (1986) Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care 24:67–74PubMedCrossRefGoogle Scholar
  18. 18.
    Val JA, Amoros BG, Martinez VP, et al (1992) Descriptive study of patient compliance in pharmacologic antihypertensive treatment and validation of the Morisky and Green test. Aten Primaria 10:767–770PubMedGoogle Scholar
  19. 19.
    Badia X, Roset M, Montserrat S, et al (1999) The Spanish version of EuroQol: a description and its applications. European quality of life scale. Med Clin 112 [Suppl 1]:79–85Google Scholar
  20. 20.
    Jamal SA, Ridout R, Chase C, et al (1999) Bone mineral density testing and osteoporosis education improve lifestyle behaviors in premenopausal women: a prospective study. J Bone Miner Res 14:2143–2149PubMedCrossRefGoogle Scholar
  21. 21.
    Farmer KC (1999) Methods for measuring and monitoring medication regimen adherence in clinical trials and clinical practice. Clin Ther 21:1074–1090CrossRefPubMedGoogle Scholar
  22. 22.
    Tosteson AN, Grove MR, Hammond CS, et al (2003) Early discontinuation of treatment for osteoporosis. Am J Med 115:209–216CrossRefPubMedGoogle Scholar
  23. 23.
    Papaioannou A, Ioannidis G, Adachi JD, et al (2003) Adherence to bisphosphonates and hormone replacement therapy in a tertiary care setting of patients in the CANDOO database. Osteoporos Int 14:808–813CrossRefPubMedGoogle Scholar
  24. 24.
    Badia X, Diez-Perez A, Alvarez-Sanz C, et al (2001) Measuring quality of life in women with vertebral fractures due to osteoporosis: a comparison of the OQLQ and QUALEFFO. Qual Life Res 10:307–317CrossRefPubMedGoogle Scholar
  25. 25.
    Badia X, Diez-Perez A, Lahoz R, et al (2004) The ECOS-16 questionnaire for the evaluation of health related quality of life in post-menopausal women with osteoporosis. Health Qual Life Outcomes 2:41CrossRefPubMedGoogle Scholar
  26. 26.
    Cote I, Farris K, Feeny D (2003) Is adherence to drug treatment correlated with health-related quality of life? Qual Life Res 12:621–633CrossRefPubMedGoogle Scholar
  27. 27.
    Billups SJ, Malone DC, Carter BL (2000) The relationship between drug therapy noncompliance and patient characteristics, health-related quality of life, and health care costs. Pharmacotherapy 20:941–949CrossRefPubMedGoogle Scholar
  28. 28.
    Holzemer WL, Corless IB, Nokes KM, et al (1999) Predictors of self-reported adherence in persons living with HIV disease. AIDS Patient Care STDS 13:185–197PubMedCrossRefGoogle Scholar
  29. 29.
    Campbell MK, Mollison J, Steen N, Grimshaw JM, Eccles M (2000) Analysis of cluster randomized trials in primary care: a practical approach. Fam Pract 17:192–196PubMedCrossRefGoogle Scholar

Copyright information

© International Osteoporosis Foundation and National Osteoporosis Foundation 2005

Authors and Affiliations

  • M. Guilera
    • 1
  • M. Fuentes
    • 2
  • M. Grifols
    • 3
  • J. Ferrer
    • 4
  • X. Badia
    • 1
  • OPTIMA study investigators
  1. 1.Health Outcomes Research EuropeBarcelonaSpain
  2. 2.Centre Atenció PrimariaAlt BerguedàBarcelonaSpain
  3. 3.Medical Department EsteveBarcelonaSpain
  4. 4.Gynecolopy DepartmentHospital Central de AsturiasOviedoSpain

Personalised recommendations